ALEXANDRIA, Va., June 25 -- United States Patent no. 12,337,015, issued on June 24, was assigned to DYSTROGEN THERAPEUTICS Corp. (Chicago).
"Myoblast chimeric cells (MCCs)" was invented by Maria Siemionow (Chicago).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to methods and compositions for generating and using myoblast chimeric cells (MCCs) for treating a muscle disease, such as muscular dystrophy, where the MCCs are composed of a myoblast derived from a patient with muscle disease (MD) and a myoblast from a donor without the MD (e.g., a healthy donor). In certain embodiments, cell fusion methods are performed using 2-4, or 5, times passaged myoblasts from the MD and donor sub...